If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Clinical Lung Cancer supports inclusion and diversity
Clinical Lung Cancer is a strong supporter of diversity in science, research and medicine, and is a promoter of inclusion. The journal offers an inclusive and supportive publishing environment and stands against all forms of discrimination, bullying and harassment.
The Editorial Team commits to influencing and improving gender, racial and ethnic diversity and inclusion, and geographic representation in lung cancer research by improving these areas within the journal; e.g. the editorial board, guest editors and authors. This commitment is aligned with Elsevier’s broader ongoing inclusion & diversity efforts. Equity and inclusion in publishing is critically important for scientific excellence and innovation. We believe passionately in the power of an inclusive publishing environment, not only to do what is right, but to enrich, strengthen and advance us all.
Myung-Ju Ahn, Marvin Jonne L. Mendoza, Nick Pavlakis, Terufumi Kato, Ross A. Soo, Dong-Wan Kim, Chong Kin Liam, Te-Chun Hsia, Chee Khoon Lee, Thanyanan Reungwetwattana, Sarayut Geater, Oscar Siu Hong Chan, Naiyarat Prasongsook, Benjamin J. Solomon, Thi Thai Hoa Nguyen, Toshiyuki Kozuki, James Chih-Hsin Yang, Yi-Long Wu, Tony Shu Kam Mok, Daniel Shao-Weng Tan, Yasushi Yatabe
Mengni Guo, Ari M. VanderWalde, Xinhua Yu, Gregory A. Vidal, G. Gary Tian
Clinical Lung Cancer
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.